Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer

BACKGROUND: Trastuzumab with cisplatin and fluoropyrimidine is the standard treatment in metastatic HER2-positive gastric or gastroesophageal (GE) junction adenocarcinoma, however there is limited data on the efficacy of trastuzumab in combination with a three-drug regimen in this setting. We examin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gastric Cancer
Main Authors: Mondaca, Sebastian, Margolis, Matthew, Sanchez-Vega, Francisco, Jonsson, Philip, Riches, Jamie C., Ku, Geoffrey Y., Hechtman, Jaclyn F., Tuvy, Yaelle, Berger, Michael F., Shah, Manish A., Kelsen, David P., Ilson, David H., Yu, Kenneth, Goldberg, Zoe, Epstein, Andrew S., Desai, Avni, Chung, Vincent, Chou, Joanne F., Capanu, Marinela, Solit, David B., Schultz, Nikolaus, Janjigian, Yelena Y.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784321/
https://ncbi.nlm.nih.gov/pubmed/30088161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-018-0861-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados